GlobeNewswire

Achieve Life Sciences Announces Operational Progress Including Completion of Technology Transfer to Adare Pharma Solutions
15/04/2026
Adare Partnership Provides Supply Chain Redundancy and U.S.-based Manufacturing Capability Company Reiterates Guidance - If Approved, Cytisinicline Commercial Launch Expected in First Half of 2027 SEATTLE and VANCOUVER [...]
Folia Health Launches “BRAVE-PWS” Study to Better Understand the Real-World Experience of Prader-Willi Syndrome Caregivers
15/04/2026
BOSTON, April 15, 2026 (GLOBE NEWSWIRE) -- Folia Health announces the launch of Burden and Real-world Assessment of Caregiver Voice and Experiences in Prader-Willi syndrome (BRAVE-PWS), a fully remote observational [...]
Amarin to Report First Quarter 2026 Financial Results and Host Conference Call on April 29, 2026
15/04/2026
DUBLIN and BRIDGEWATER, N.J., April 15, 2026 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ: AMRN), a company advancing the science of cardiovascular therapeutics worldwide, today announced that it will report first [...]
Callio Therapeutics to Present Poster on CLIO-8221, a Novel Dual-Payload Antibody-Drug Conjugate, at AACR 2026
15/04/2026
Callio Therapeutics is developing novel dual-payload antibody-drug conjugates (ADCs) designed to address resistance to existing cancer therapies, using proprietary linker and ADC platform technologies CLIO-8221 is a [...]
SAB BIO to Present Additional Data Supporting the Unique Profile of SAB-142 at the 2026 Immunology of Diabetes Society Congress
15/04/2026
MIAMI, April 15, 2026 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS ), a clinical-stage biopharmaceutical company developing a fully human anti-thymocyte immunoglobulin (hATG) for type 1 diabetes (T1D) and [...]
Cue Biopharma to Present New Preclinical Data on Lead Autoimmune and Inflammatory Disease Candidate CUE-401 at IMMUNOLOGY2026
15/04/2026
BOSTON, April 15, 2026 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate disease- [...]
AliveCor Launches AI-Powered Kardia 12L in Europe: The World’s First Handheld 12-Lead ECG with a Unique Single-Cable Design
15/04/2026
Now CE Marked, the Kardia 12L ECG System leverages AI to detect 35 cardiac determinations, simplifying the ECG process and expediting access to critical heart data MOUNTAIN VIEW, Calif., April 15, 2026 (GLOBE NEWSWIRE [...]
Lancement par AliveCor du Kardia 12L alimenté par l’IA en Europe : le premier ECG portable à 12 dérivations au monde, doté d’une conception inédite à câble unique
15/04/2026
Désormais certifié CE, le système 12L utilise l’intelligence artificielle pour effectuer 35 diagnostics cardiaques, ce qui simplifie le processus d’ECG et facilite l’accès aux données cardiaques essentielles MOUNTAIN [...]
MinervaX Strengthens Executive Leadership Team with Two Strategic Appointments as it Advances its Maternal GBS Vaccine Towards Pivotal Trial Initiation
15/04/2026
The appointments of Jamila Louahed as CDO and Hans Henrik Chrois Christensen as CFO bring late ‑ stage development, global regulatory and operational expertise as MinervaX enters its next phase of growth Builds on [...]
Notice of Issuance of New Shares in Connection with the Introduction of the Employee Stock Ownership Plan, Matters Relating to Stock Units and Determination of Payment Amount and Other Matters of Issuance of New Shares Under Prior RSU Award
15/04/2026
Tokyo, Japan and Cambridge, UK, 15 April 202 6 – Nxera Pharma Co. Ltd (“Nxera” or the “Company”; TSE 4565) announces that, in connection with the introduction of the Employee Stock Ownership Plan for employees residing [...]
Tensive publishes positive interim pivotal clinical data showing REGENERA™ supports natural breast reconstruction in Updates in Surgery
15/04/2026
Advanced biomaterial device designed for use in lumpectomy surgeries Interim results from the first 25 of 94 patients at 6 months follow up Confirms REGENERA™ is safe and biocompatible as breast tissue replacement 100% [...]
CLINUVEL: advancing peptides for photomedicine and vitiligo care at AAD 2026
15/04/2026
AAD 2026 reinforces CLINUVEL’s expertise in dermatology MELBOURNE, Australia, April 15, 2026 (GLOBE NEWSWIRE) -- CLINUVEL’s innovative photomedicine and vitiligo programs featured extensively at the recent American [...]
Aerska Strengthens Leadership and Board with Key Appointments to Advance Systemically Delivered RNA Medicines for the Brain
15/04/2026
Stuart Milstein appointed Chief Platform Officer, bringing decades of experience in oligonucleotide drug development to underpin Aerska’s platform R&D Lisa Taylor Ash joins Board of Directors, strengthening [...]
Citryll Strengthens Intellectual Property Portfolio With Grant of European Composition of Matter Patent for CIT-013
15/04/2026
Expected to provide exclusivity into 2039 Oss, Netherlands – 15 April 2026 – Citryll, a biotech company pioneering a transformative approach to treating immune-mediated inflammatory diseases by targeting Extracellular [...]
OSE Immunotherapeutics to Present a Novel, First-in-Class, FPR2 Agonist Monoclonal Antibody in the Resolution of Chronic Inflammation at the AAI 2026 Meeting
15/04/2026
Nantes, France, April 15, 2026 – 7:30am CEST - OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) , a clinical-stage biotech company dedicated to developing first-in-class therapies in immuno-oncology and immuno [...]
OSE Immunotherapeutics présentera un nouvel anticorps monoclonal, first-in-class, agoniste de FPR2 dans la résolution de l’inflammation chronique au Congrès 2026 de l’AAI
15/04/2026
Nantes, France, 15 avril 2026 – 7h30 CEST – OSE Immunotherapeutics SA (ISIN : FR0012127173 ; Mnemo : OSE) , une société de biotechnologie au stade clinique développant des thérapies first-in-class en immuno-oncologie et [...]
BioVersys to Present Data on Clinical and Preclinical Pipeline Programs at ESCMID Global 2026
15/04/2026
BASEL, Switzerland, April 15, 2026 (GLOBE NEWSWIRE) -- Poster presentations to feature data from clinical asset BV100 addressing carbapenem-resistant Acinetobacter baumannii-calcoaceticus complex (CRABC) hospital [...]
Vivoryon Therapeutics N.V. to Report Full Year 2025 Financial Results and Business Updates on April 23, 2026
15/04/2026
Vivoryon Therapeutics N.V. to Report Full Year 2025 Financial Results and Business Updates on April 23, 2026 Halle (Saale) / Munich, Germany, April 15 , 2026 - Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; [...]
Revolution Medicines, Inc. Prices $2.0 Billion in Concurrent Upsized Offerings of Common Stock and Convertible Senior Notes
15/04/2026
REDWOOD CITY, Calif., April 15, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced the pricing of [...]

Pages

Other news

Test 2

Lorem ipsum

Test 1

Lorem upsum